Team discovers a piece of the puzzle for individualized cancer therapy via gene silencing

May 26, 2010

In a major cancer-research breakthrough, researchers at the McGill University, Department of Biochemistry have discovered that a small segment of a protein that interacts with RNA can control the normal expression of genes - including those that are active in cancer.

The research, published online on May 26, 2010 by the prestigious journal Nature, has important immediate applications for laboratory research and is another step toward the kind of individualized therapies researchers are pursuing vigorously around the world.

Human cells need to produce the correct proteins at the right time and in the appropriate quantities to stay healthy. One of the key means by which cells achieve this control is by "", a form of where small pieces of RNA, called micro RNAs, obstruct the production of specific proteins by interacting with their . However, not any piece of RNA can do this. Dr. Bhushan Nagar and graduate student Filipp Frank, in collaboration with Dr. Nahum Sonenberg at McGill's new Life Sciences Complex, used structural biology to unravel how a small segment in the Argonaute proteins, the key molecules of RNA interference, can select the correct micro RNAs.

This video is not supported by your browser at this time.
In a major cancer-research breakthrough, researchers at the McGill University, Department of Biochemistry have discovered that a small segment of a protein that interacts with RNA can control the normal expression of genes -- including those that are active in cancer. Credit: Media Relations, McGill University.

In doing so, the team has discovered that Argonaute proteins can potentially be exploited to enhance gene silencing. "RNA interference could be used as a viable therapeutic approach for inhibiting specific genes that are aberrantly active in diseases such as cancer", Nagar said. "We now have a handle on being able to rationally modify micro RNAs to make them more efficient and possibly into therapeutic drugs."

While therapeutic applications are many years away, this new insight provides an avenue to specifically control the production of proteins, which in for example, are abnormal.

"This is fantastic news," said Dr. David Thomas, Chair of McGill's Department of Biochemistry. "You've seen stories lately about how we may see the end of chemotherapy? Well, this is part of that path in developing genetically based therapies that can be tailored to individual patients' particular illnesses. It's a great step forward."

Explore further: Unplanned hospitalizations with GI cancer patients common

Related Stories

Researchers find key to messenger RNA control

Jul 26, 2007

Researchers at McGill University have successfully used a class of tiny nucleic acids called microRNAs to control messenger RNA, one of the major gene regulators in life, outside the confines of a living cell for the first ...

Researchers discover how microRNAs control protein synthesis

Jul 09, 2007

While most RNAs work to create, package, and transfer proteins as determined by the cell’s immediate needs, miniature pieces of RNA, called microRNAs (miRNAs) regulate gene expression. Recently, researchers from the University ...

Researchers discover RNA repair system in bacteria

Oct 12, 2009

In new papers appearing this month in Science and the Proceedings of the National Academy of Sciences, University of Illinois biochemistry professor Raven H. Huang and his colleagues describe the first RNA repair system to be ...

The RNA drug revolution -- a new approach to gene therapy

Jan 23, 2008

RNA interference (RNAi) represents an innovative new strategy for using small RNA molecules to silence specific genes associated with disease processes, and a series of review articles describing the state-of-the-art and ...

Weakened RNA interference reduces survival in ovarian cancer

Dec 17, 2008

Levels of two proteins in a woman's ovarian cancer are strongly associated with her likelihood of survival, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports in the Dec. 18 ...

Recommended for you

Blood biomarker may detect lung cancer

6 hours ago

A new study shows that patients with stage I to stage III non-small cell lung cancer have different metabolite profiles in their blood than those of patients who are at risk but do not have lung cancer. The study abstract ...

ACG: Recent increase in incidence of young-onset CRC

22 hours ago

(HealthDay)—The incidence of young-onset colorectal cancer (CRC) is increasing, and the disease is more aggressive pathologically. These findings are being presented at the annual meeting of the American ...

User comments : 0